The management of atrial fibrillation in heart failure

Current Treatment Options in Cardiovascular Medicine

Volumn 8, Issue 4, 2006, Pages 325-333

  Bala, Rupa ^b   Callans, David J ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIGITALIS; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; ESMOLOL; IRBESARTAN; METOPROLOL; TRANDOLAPRIL; WARFARIN;

ARTIFICIAL HEART PACEMAKER; ASTHMA; ATAXIA; BRADYCARDIA; CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSTIPATION; CORNEA DISEASE; DIGITALIS INTOXICATION; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART FAILURE; HEART HEMODYNAMICS; HEART PACING; HEART PERFORMANCE; HEART PROARRHYTHMIA; HEART RHYTHM; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; HYPOTENSION; HYPOTHYROIDISM; LIVER TOXICITY; LUNG TOXICITY; MYOPATHY; NEUTROPENIA; NONHUMAN; OPTIC NERVE DISEASE; PARESTHESIA; PHOTOSENSITIVITY DISORDER; REVIEW; SKIN DISCOLORATION; SYMPTOMATOLOGY; TACHYCARDIA; THROMBOEMBOLISM; THYROID DISEASE; TORSADE DES POINTES; TREATMENT INDICATION;

EID: 33746307847     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-006-0053-3     Document Type: Review

References (35)

1. Kannel WB, Abbott RD, Savage DD, et al.: Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982, 306:1018-1022.
2. Maisel WH, Stevenson LW: Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003, 91:2D-8D.
3. Benjamin EJ, Wolf PA, D'Agostino RB, et al.: Impact on atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98:946-952.
4. Ehrlich JR, Nattel S, Hohnloser SH: Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol 2002, 13:399-405.
5. Carson PE, Johnson GR, Dunkman EB, et al.: The influence of atrial fibrillation on prognosis in mild to moderate heart failure. Circulation 1993, 87(suppl VI):VI102-VI110.
6. Crijns HJ, Tjeerdsma G, de Kam PJ, et al.: Prognostic value of the presence of atrial fibrillation in patients with advanced heart failure. Eur Heart J 2000, 21:1238-1245.
7. Mahoney P, Kimmel S, DeNofrio D, et al.: Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Am J Cardiol 1999, 83:1544-1547.
8. Dries DL, Exeter DV, Gersh BL et al.: Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998, 32:695-703.
9. Middlekauf HR, Stevenson WG, Stevenson LW: Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation 1991, 84:40-48.
10. Mathew J, Hunsberger S, Fleg J, et al.: Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 2000, 118:914-922.
11. Nattel S, Shiroshita A, Cardin S, et al.: Mechanisms for atrial remodeling and clinical relevance. Curr Opin Cardiol 2004, 20:21-25.
12. Sanders P, Morton JB, Davidson NC, et al.: Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 2003, 108:1461-1468.
13. Fenelon G, Wijns W, Andries E, et al.: Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol 1996, 19:95-106.
14. Haissaguerre M, Jais P, Shah DC, et al.: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998, 339:659-666.
15. Hsu LF, Jais P, Sanders P, et al.: Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004, 351:2373-2383.
16. Chen MS, Marrouche NF, Khaykin Y, et al.: Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 2004, 43:1004-1009.
17. Fuster V, Rydén LE, Asinger RW, et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2001, 38:1231-1265.
18. Naccarelli GV, Hynes BJ, Wolbrette DL, et al.: Atrial fibrillation in heart failure: prognostic significance and management. J Cardiovasc Electrophysiol 2003, 14(suppl):S281-S286.
19. Hohnloser SH, Kuck KH, Lilienthal J: Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet 2000, 356:1789-1794.
20. Van Gelder IC, Hagens VE, Bosker HA, et al.: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834-1840.
21. Wyse DG, Waldo AL, DiMarco JP, et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. N Engl J Med 2002, 347:1825-1833.
22. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial [no authors listed]. Am Heart J 2002, 144:597-607.
23. Khand AU, Rankin AC, Martin W, et al.: Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure. J Am Coll Cardiol 2003, 42:1944-1951.
24. Naccarelli GV, Wolbrette DL, Khan M, et al.: Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003, 91(suppl):15D-26D.
25. Echt DS, Liebson PR, Mitchell LB, et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991, 324:781-788.
26. Deedwania PC, Singh BN, Ellenbogen K, et al.: Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Anti-arrhythmic Therapy (CHF-STAT). Circulation 1998, 98:2574-2579.
27. Singh S, Zoble RG, Yellen L, et al.: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study. Circulation 2000, 102:2385-2390.
28. Pederson OD, Bagger H, Keller N, et al.: Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy. Circulation 2001, 104:292-296.
29. Pratt CM, Singh S, Hussein R, et al.: The efficacy of azmilide in the treatment of atrial fibrillation in the presence of left ventricular systolic function: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol 2004, 43;1211-1216.
30. Nakashima H, Kumagai K, Urata H, et al.: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000, 101:2612-2617.
31. Pedersen OD, Bagger H, Køber L, et al.: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999, 100:376-380.
32. Madrid AH, Bueno MG, Rebollo JMG, et al.: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002, 106:331-336.
33. Wood MA, Brown-Mahoney C, Kay GN, et al.: Clinical outcomes after ablation and pacing therapy for atrial fibrillation - a meta-analysis. Circulation 2000, 101:1138-1144.
34. Doshi RN, Daoud EG, Fellows C, et al.: Left ventricular-based cardiac stimulation Post AV Nodal Ablation Evaluation (The PAVE Study). J Cardiovasc Electrophysiol 2005, 16:1160-1165.
35. Khargi K, Hutten BA, Lemke B, et al.: Surgical treatment of atrial fibrillation; a systematic review. Eur J Cardiothorac Surg 2005, 27:258-265.